Fennec Pharmaceuticals Inc. (FENC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
68 TW Alexander Drive
Research Triangle Park, NC 27709
United States of America (the)
Phone
919 636 4530
Website
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
September 15, 2017
| Name | Title | Pay | Year Born |
| Jeffrey S. Hackman | Chief Executive Officer & Director | 632,176 | 1963 |
| Pierre S. Sayad | Chief Medical Officer | 464,081 | N/A |
| Robert C. Andrade | Chief Financial Officer | 552,646 | 1975 |
| Lei Fang | President of Pharstat Inc | 0 | N/A |
| Mark Gowland | Controller | 0 | N/A |
| Terry Evans | Chief Commercial Officer | 0 | N/A |
| Christiana Cioffi | Chief Strategy Officer | 0 | N/A |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.